Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder

BACKGROUND: We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with major depressive disorder. METHODS: We conducted a 6-week, double-blind, placebo-controlled, parallel-group, Phase II, proof-of-concept study. Patients with major depressive disor...

Descripción completa

Detalles Bibliográficos
Autores principales: Connor, Kathryn M, Ceesay, Paulette, Hutzelmann, Jill, Snavely, Duane, Krystal, Andrew D, Trivedi, Madhukar H, Thase, Michael, Lines, Christopher, Herring, W Joseph, Michelson, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570043/
https://www.ncbi.nlm.nih.gov/pubmed/28582570
http://dx.doi.org/10.1093/ijnp/pyx033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570043/
https://www.ncbi.nlm.nih.gov/pubmed/28582570
http://dx.doi.org/10.1093/ijnp/pyx033

Ejemplares similares